EP1623712A2 — Selective estrogen receptor modulator in combination with dehydroepiandrosterone (DHEA) or analogues
Assigned to Endorecherche Inc · Expires 2006-02-08 · 20y expired
What this patent protects
Novel methods for the medical treatment and/or inhibition of the development of breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warmblooded animals including humans involving administration of selective estrogen receptor modulator and an amou…
USPTO Abstract
Novel methods for the medical treatment and/or inhibition of the development of breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warmblooded animals including humans involving administration of selective estrogen receptor modulator and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3β,17β-diol, and compounds converted in vivo to one of the foregoing precursors. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursors is disclosed. Pharmaceutical compositions for delivery of active ingredients and kits useful to the invention are disclosed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.